These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 25001080

  • 1. Similar names for similar biologics.
    Casadevall N, Felix T, Strober BE, Warnock DG.
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [Abstract] [Full Text] [Related]

  • 2. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J.
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
    Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.
    Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
    [Abstract] [Full Text] [Related]

  • 5. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B, Zuñiga L.
    BioDrugs; 2012 Dec 01; 26(6):357-61. PubMed ID: 23030677
    [Abstract] [Full Text] [Related]

  • 6. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S.
    Cancer Med; 2014 Aug 01; 3(4):889-99. PubMed ID: 24810680
    [Abstract] [Full Text] [Related]

  • 7. Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics.
    Tomaszewski D.
    J Manag Care Spec Pharm; 2016 Aug 01; 22(8):919-26. PubMed ID: 27459654
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biosimilar safety factors in clinical practice.
    Reinisch W, Smolen J.
    Semin Arthritis Rheum; 2015 Jun 01; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [Abstract] [Full Text] [Related]

  • 10. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS, Ehrenpreis ED, Kulkarni PM, FDA-Related Matters Committee of the American College of Gastroenterology.
    Am J Gastroenterol; 2014 Dec 01; 109(12):1856-9. PubMed ID: 24957160
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
    Afzali A, Furtner D, Melsheimer R, Molloy PJ.
    Adv Ther; 2021 May 01; 38(5):2077-2093. PubMed ID: 33745111
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E, Ramanan S, Green L.
    J Manag Care Spec Pharm; 2015 Jul 01; 21(7):532-9. PubMed ID: 26108377
    [Abstract] [Full Text] [Related]

  • 19. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S, Getz K.
    Drug Saf; 2015 Aug 01; 38(8):687-92. PubMed ID: 26108298
    [Abstract] [Full Text] [Related]

  • 20. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R, Lavernia F, Edelman S.
    Endocr Pract; 2018 Feb 01; 24(2):195-204. PubMed ID: 29466056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.